LPA, lipoprotein(a), 4018

N. diseases: 340; N. variants: 49
Disease: Venous Thromboembolism ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 GeneticVariation phenotype BEFREE <i>Objectives.</i> Evidence from case-control studies as well as meta-analyses of these study designs suggest elevated lipoprotein(a) [Lp(a)] to be associated with an increased risk of venous thromboembolism (VTE). 31032650 2019
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 Biomarker phenotype BEFREE Before starting TT, we suggest screening for FVL, lipoprotein(a), and the lupus anticoagulant to identify patients at increased VTE risk, with an adverse risk-to-benefit ratio for TT. 30577621 2018
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 Biomarker phenotype BEFREE So we assume a role of lipoprotein(a) as predictor of venous thromboembolism in neoplastic patients. 27822883 2017
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 Biomarker phenotype BEFREE Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-analysis of the Literature. 28346964 2017
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 GeneticVariation phenotype BEFREE Aim of the study was to investigate the role of LPA gene KIV-2 size polymorphism and single nucleotide polymorphisms (SNPs) (rs1853021, rs1800769, rs3798220, rs10455872) in modulating VTE susceptibility. 26900838 2016
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 Biomarker phenotype BEFREE The 2 LPA variants were combined and examined as LPA scores for the association with ischemic stroke (and TOAST [Trial of Org 10172 in Acute Stroke Treatment] subtypes) (effective sample size [n(e)] = 9,396); peripheral arterial disease (n(e) = 5,215); abdominal aortic aneurysm (n(e) = 4,572); venous thromboembolism (n(e) = 4,607); intracranial aneurysm (n(e) = 1,328); CAD (n(e) = 12,716), carotid intima-media thickness (n = 3,714), and angiographic CAD severity (n = 5,588). 22898070 2012
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 GeneticVariation phenotype BEFREE Furthermore, a significant association with recurrent VTE was found for all IT traits except the factor V variant and elevated lipoprotein(a). 18779442 2008
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 AlteredExpression phenotype BEFREE Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy. 12638077 2003
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 AlteredExpression phenotype BEFREE Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. 14656611 2003
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 GeneticVariation phenotype BEFREE Our aim was to assess the contributions of high levels of factor VIII:C, factor XI:C, thrombin activatable fibrinolysis inhibitor (TAFI) and lipoprotein (a) (Lp(a)) to the risk of venous thromboembolism in factor V Leiden carriers. 12368162 2002
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 AlteredExpression phenotype BEFREE Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. 11071628 2000
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.100 Biomarker phenotype BEFREE Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. 10449697 1999